Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Shaw Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Battling Blood-Sucking Bugs
      • Unexpected Leads to Curb Addiction
      • Shaping Therapies for Sickle Cell Disease
      • The Mind’s Map Maker
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
The NIH Catalyst: A Publication About NIH Intramural Research

National Institutes of Health • Office of the Director | Volume 28 Issue 2 • March–April 2020

Research Briefs: Coronavirus Research

Highlights

When COVID-19—a respiratory disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus (SARS-CoV-2)—was first detected in December 2019 in Wuhan, Hubei Province, China, NIAID intramural and extramural scientists mobilized quickly to study the virus. Key areas of investigation include conducting basic research on its origins and how it causes disease, and developing animal study models, new treatments, and vaccines. For more information on the coronavirus, go to https://www.nih.gov/health-information/coronavirus.


COVID-19 A REMINDER OF THE CHALLENGE OF EMERGING INFECTIOUS DISEASES

In a New England Journal of Medicine commentary, NIAID Director Anthony S. Fauci, NIAID Deputy Director for Clinical Research and Special Projects H. Clifford Lane, and CDC Director Robert R. Redfield shared their observations about COVID-19. The authors pointed to the many research efforts now underway including numerous vaccine candidates proceeding toward early-stage clinical trials as well as clinical trials already underway to test candidate therapeutics, including an NIAID-sponsored trial of the experimental antiviral drug remdesivir that began enrolling participants on February 21, 2020. “The COVID-19 outbreak is a stark reminder of the ongoing challenge of emerging and re-emerging infectious pathogens and the need for constant surveillance, prompt diagnosis and robust research to understand the basic biology of new organisms and our susceptibilities to them, as well as to develop effective countermeasures,” the authors concluded. (A.S. Fauci, H.C. Lane, and R.R. Redfield, N Engl J Med, 2020; DOI:10.1056/NEJMp2002387)


NIH CLINICAL TRIAL OF REMDESIVIR TO TREAT COVID-19 BEGINS

In February 2020, a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) has begun at the University of Nebraska Medical Center’s biocontainment unit (Omaha, Nebraska). NIAID is the trial’s regulatory sponsor. This is the first clinical trial in the United States to evaluate an experimental treatment for COVID-19. The first participant is an American who was repatriated after being quarantined on the Diamond Princess cruise ship in Japan. For more information go to https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins or visit http://www.ClinicalTrials.gov and search identifier NCT04280705.


STRUCTURAL BIOLOGY POINTS WAY TO CORONAVIRUS VACCINE

Excerpts from the NIH Director’s Blog (posted on March 3, 2020)

colorful 3D model of protein; looks like a vase of flowers

CREDIT: NIAID

3D print of a spike protein on the surface of the novel coronavirus SARS-CoV-2. Spike proteins cover the surface of SARS-CoV-2 and enable the virus to enter and infect human cells.

NIH-funded researchers including Jason McLellan, an alumnus of the NIAID’s Vaccine Research Center (VRC) and now at The University of Texas at Austin, have been studying coronaviruses in collaboration with NIAID investigators for years, with special attention to the spike proteins. Just two weeks after Chinese scientists reported the first genome sequence of the virus, McLellan and his colleagues designed and produced samples of its spike protein. Importantly, his team had earlier developed a method to lock coronavirus spike proteins into a shape that makes them both easier to analyze structurally via the high-resolution imaging tool cryoelectron microscopy and to use in vaccine-development efforts.

After locking the spike protein in the shape it takes before fusing with a human cell to infect it, the researchers reconstructed its atomic-scale 3D structural map in just 12 days. Their results, published in Science, confirm that the spike protein on the virus that causes COVID-19 is quite similar to that of its close relative the SARS virus. It also appears to bind human cells more tightly than the SARS virus does, which may help to explain why the new coronavirus appears to spread more easily from person to person, mainly by respiratory transmission. (NIH authors: K.S. Corbett, O. Abiona, B.S. Graham, and J.S. McLellan (NIH alum), Science pii:eabb2507, 2020; DOI:10.1126/science.abb2507)

McLellan’s team and his NIAID VRC counterparts also plan to use the stabilized spike protein as a probe to isolate naturally produced antibodies from people who’ve recovered from COVID-19. Such antibodies might form the basis of a treatment for people who’ve been exposed to the virus, such as health-care workers.

The NIAID is now working with the biotechnology company Moderna (Cambridge, Massachusetts) to use the latest findings to develop a vaccine candidate. The goal is to direct the body to produce a spike protein in such a way to elicit an immune response and the production of antibodies. An early clinical trial of the vaccine in people is expected to begin in the coming weeks. Other vaccine candidates are also in preclinical development.

This page was last updated on Tuesday, March 29, 2022

  • Issue Overview
  • Features
    • Remdesivir Is Active Against MERS Coronavirus in Monkeys
    • Five New Lasker Scholars
    • A Giant Leap of Love, Faith, and Courage
    • Blood Test May Point to Timing of Breast-Cancer Diagnosis
    • Improving End-of-Life Care for Dying Children
  • Departments
    • Research Briefs: Coronavirus Research
    • From the Deputy Director for Intramural Research
    • Photographic Moment
    • Technology Transfer: Biologically Engineered Pacemaker
    • Colleagues: Recently Tenured
    • From the Annals of NIH History
    • The Training Page: From the Fellows Committee
    • Research Briefs
    • The SIG Beat: Flow Cytometry Winter Meeting
    • The SIG Beat
    • Announcements
  • Issue Contents
  • Download this issue as a PDF

Catalyst menu

  • Current Issue
  • Previous Issues
  • About The NIH Catalyst
  • Contact The NIH Catalyst
  • Share Your Story
  • NIH Abbreviations

Subscribe Today!

Subscribe to The NIH Catalyst Newsletter and receive email updates.

Subscribe

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search